<?xml version="1.0" encoding="UTF-8"?>
<p>Tedaniophorbasins A (
 <bold>1</bold>) and B (
 <bold>2</bold>) were tested for their ability to inhibit the growth of chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains of the malaria parasite 
 <italic>Plasmodium falciparum</italic> [
 <xref rid="B21-marinedrugs-19-00095" ref-type="bibr">21</xref>], inhibition of the growth of the trypanosome 
 <italic>Trypanosoma brucei brucei</italic> [
 <xref rid="B22-marinedrugs-19-00095" ref-type="bibr">22</xref>], and cytotoxicity towards pancreatic (Bx-PC-3, Panc-1, and Su-86-86) and breast cancer (BT-474, MCF-10A, and MDA-MB-231) cell lines [
 <xref rid="B23-marinedrugs-19-00095" ref-type="bibr">23</xref>] (assays that we routinely run in our labs), however, both compounds were inactive against all targets at the highest concentration (40 ÂµM) tested.
</p>
